Aside from the major products that are out there right now, there's one really for dealing with severe burns and diabetic ulcers. Essentially, skin stem cells are transplanted over the wound. I think about a quarter of a million patients have been treated with that product. The numbers are growing by 50,000 to 100,000 a year.
Part of the challenge, and it's going to be a challenge as we get into the delivery of therapies later on, is that it's not just about developing a therapy that works: there's a whole challenge in having that adopted as the standard of care in the hospitals and in clinicians being ready to use it and accept it, because that's the way to move forward. Our challenges don't end once we get something into the clinic. It's going to be an ongoing process. Burn victims are one, and the others are cartilage repairs and tendon repairs, and drugs as well.